Mannkind Corp
NASDAQ:MNKD 4:00:00 PM EDT
| Market Cap (Intraday) | 1.13B |
| Current PE | N/A |
| Forward PE | 32.23 |
| 2yr Forward PE | 16.76 |
| 10-Day MA | $4.19 |
| 50-Day MA | $4.30 |
| 200-Day MA | $4.10 |
Mannkind Corp Stock, NASDAQ:MNKD
1 Casper Street, Suite 300, Danbury, Connecticut 06810
United States of America
Phone: +1.818.661.5000
Number of Employees: 414
Description
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.